STOCK TITAN

Corcept Therapeutics (CORT) DEF 14A Filings

CORT NASDAQ

Here are the DEF 14A proxy statements from Corcept Therapeutics Inc. (CORT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORT filings page.

Rhea-AI Summary

Corcept Therapeutics is asking stockholders to vote at its May 21, 2026 annual meeting on four main items: electing eight directors, ratifying Ernst & Young as auditor, approving executive pay on an advisory basis and amending the 2024 Incentive Award Plan to add more shares.

The proxy details 107,356,686 common shares outstanding as of April 9, 2026 and shows significant 2025 business progress, including revenue rising from $675.0 million in 2024 to $761.4 million and advancement of relacorilant and other cortisol modulators in oncology and metabolic indications. Executive pay is heavily equity-based, with CEO Joseph Belanoff’s 2025 package including $1.19 million salary, a matching $1.19 million bonus and options valued at about $12.9 million.